CNTNAP4 signaling regulates osteosarcoma disease progression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Sarcoma treatment requires understanding molecular drivers of disease progression.
• NELL-1, a secreted glycoprotein, influences osteosarcoma (OS) progression by altering the extracellular matrix (ECM) and cell-ECM interactions.
• Contactin-associated protein-like 4 (Cntnap4) is a NELL-1 interactor involved in nervous system functions.

Purpose of the Study:

• To investigate the role of Cntnap4 in sarcoma progression.
• To elucidate the NELL-1/Cntnap4 signaling pathway in osteosarcoma.
• To assess the therapeutic potential of targeting this pathway in sarcomas.

Main Methods:

• CRISPR/Cas9 gene deletion of CNTNAP4 in osteosarcoma cells.
• Assessment of tumor growth, angiogenesis, and metastasis.
• Analysis of cell attachment, migration, and invasion.
• Transcriptomic and phospho-array analysis to identify signaling pathways.
• Validation in human primary sarcoma cells and tissues.

Main Results:

• CNTNAP4 gene deletion reduced OS tumor growth, angiogenesis, and metastasis.
• CNTNAP4 knockout (KO) phenocopied NELL-1 KO effects, reducing cell attachment, migration, and invasion.
• CNTNAP4 KO cells were unresponsive to NELL-1, indicating pathway dependence.
• CNTNAP4 deletion reduced MAPK/ERK signaling; ERK1/2 agonist restored cell functions.
• CNTNAP4 signaling is significant in human sarcomas.

Conclusions:

• The NELL-1/CNTNAP4 signaling axis is crucial for human sarcoma progression.
• CNTNAP4 plays a key role in mediating NELL-1's effects on sarcoma cells.
• Targeting the NELL-1/CNTNAP4 pathway presents a potential therapeutic strategy for sarcoma treatment.